Seer
Proteomics company pioneering new technologies to decode the secrets of the proteome and enable early disease detection. Publicly traded on NASDAQ (SEER). Developed the Proteograph platform for deep proteome analysis.
Notes
Seer is a life sciences company pioneering new technologies in proteomics to decode the secrets of the proteome. The company is publicly traded on NASDAQ under the ticker symbol SEER and is headquartered in Redwood City, California.
The company developed the Proteograph platform, which uses engineered nanoparticles to enable deep, unbiased proteome analysis at scale. This technology allows researchers to analyze thousands of proteins simultaneously, enabling applications in early disease detection, drug development, and precision medicine.
Seer's technology addresses a key bottleneck in proteomics research - the ability to comprehensively analyze the proteome in a scalable and reproducible manner.
Team
- Omid Farokhzad, M.D. - Founder & Chief Executive Officer
- LinkedIn: linkedin.com/in/omidfarokhzad
- David Horn - Chief Financial Officer
- Daniel Hornburg, Ph.D. - Chief Technology Officer
Additional Research Findings
- NASDAQ: SEER (publicly traded)
- Portfolio company of aMoon
- Proteograph platform for deep proteome analysis
- Engineered nanoparticle technology
- Focus on early disease detection
- Redwood City, California headquarters
- Founded in 2017
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| aMoon | Tel Aviv, Israel | biotech-focused | series-aseries-b+2 | 8 |